USRM (US Stem Cell) Mohanram G-Score: 2 (As of Dec. 2022) — 33% Below Median


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Mohanram G-Score?

US Stem Cell USRM -99.00% 12 Mohanram G-Score is 2 as of Dec. 2022, which is 33% below its 10-year median of 3.00. GuruFocus rates USRM with a GF Score™ of 12/100.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

US Stem Cell has an G-score of 2.

The historical rank and industry rank for US Stem Cell's Mohanram G-Score or its related term are showing as below:

USRM' s Mohanram G-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 2

During the past 13 years, the highest Piotroski G-score of US Stem Cell was 4. The lowest was 1. And the median was 3.

US Stem Cell  (OTCPK:USRM) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


US Stem Cell Mohanram G-Score Related Terms


US Stem Cell Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Mohanram G-Score Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 2.00 2.00 2.00

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 2.00

USRM vs NOVNQ, RGRX, NMTRQ: Mohanram G-Score Comparison

For the Biotechnology subindustry, US Stem Cell's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell Mohanram G-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Mohanram G-Score falls into.


USRM
12GF Score
US Stem Cell Inc USRM
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

US Stem Cell has an G-score of 2.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 2 mean?
US Stem Cell (USRM) has a Mohanram G-Score of 2 as of Dec. 2022. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on US Stem Cell and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, US Stem Cell's Mohanram G-Score has ranged from 1.00 to 4.00.
Is US Stem Cell's Mohanram G-Score too high?
US Stem Cell's current Mohanram G-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Mohanram G-Score compare to NOVNQ and RGRX?
US Stem Cell's Mohanram G-Score of 2 can be compared against companies in the Biotechnology industry. Historically, US Stem Cell's own Mohanram G-Score has ranged from 1.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Biotechnology company?
A good Mohanram G-Score depends on the Biotechnology industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on US Stem Cell and its competitors. US Stem Cell's current Mohanram G-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Mohanram G-Score of 2. The current Mohanram G-Score is 2, which is 33% below median its 10-year median of 3.00. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For US Stem Cell (USRM), the current Mohanram G-Score is 2 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price